Novelties in Medicinal Therapy of Uncontrolled Arterial Hypertension: SGLT2 Inhibitors and What Else?

AUTHOR(S) / АУТОР(И): Rodolfo Fernando Rivera

Download Full Pdf   

DOI: 10.46793/KARNEF25.328R

ABSTRACT / САЖЕТАК:

Uncontrolled arterial hypertension (UAH remains one of the most challenging conditions in clinical practice, often exposing patients and clinicians to persistently elevated blood pressure (BP) levels despite optimal use of standard antihypertensive therapies. In this context, sodium-glucose co-transporter 2 inhibitors (SGLT2i), initially developed for the treatment of type 2 diabetes mellitus (T2DM), are emerging as promising agents in the management of BP regulation.

Growing evidence demonstrates that these agents can effectively lower BP not only in patients with T2DM, but also in individuals with UAH, chronic kidney disease (CKD), and congestive heart failure (CHF), with effects that are sometimes independent of glycemic control. Unlike traditional anti-hypertensives, SGLT2 inhibitors exert multifactorial actions: they promote controlled osmotic diuresis, reduce plasma volume, improve endothelial function, and modulate sympathetic nervous system activity. This integrated approach facilitates more physiologic and sustainable BP control, opening new therapeutic avenues, particularly for patients with cardio-metabolic and renal comorbidities.

This chapter explores the role of SGLT2i in the treatment of hypertension, with a focus on their mechanisms of action, recent clinical evidence, and future implications. The introduction of this drug class may represent a paradigm shift in the management of UAH, offering new opportunities for more effective and individualized therapeutic strategies.

 KEYWORDS / КЉУЧНЕ РЕЧИ:

uncontrolled arterial  hypertension, sodium- glucose co-transporter2 inhibitors, blood pressure regulation

REFERENCES / ЛИТЕРАТУРА:

• Li M, Yi T, Fan F, Qiu L, Wang Z, Weng H, et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):139.
• Selvaraj S, Vaduganathan M, Claggett BL, et al. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. JACC Heart Fail. 2023;11(1):76-89.
• Baker WL, Buckley LF, Kelly MS, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6(5):e005686.
• Gupta R, Maitz T, Egeler D, et al. SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure. Trends Cardiovasc Med. 2023;33(8):479-486.
• Serenelli M, Böhm M, Inzucchi SE, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the DAPA-HF trial. Eur Heart J. 2020;41(36):3402-3418.
• Furtado RHM, Raz I, Goodrich EL, et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 2022;145(21):1581-1591.
• Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180-93.
• Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393-405.
• Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy. Lancet Diabetes Endocrinol. 2016;4(3):211-220.
• Borrelli S, Garofalo C, Reboldi G, et al. Changes in 24-hour blood pressure profile after 12 weeks of dapagliflozin treatment in patients with diabetic kidney disease: an Italian multicenter prospective study. Clin Kidney J. 2024;17(11):sfae316.